Merck Ends Nemtabrutinib Development After Risk-Benefit Review
Merck will discontinue Phase 3 trials BELLWAVE-011, BELLWAVE-008 and BELLWAVE-010 after reviewing the program’s data. Analyses are ongoing.
Merck is discontinuing Phase 3 BELLWAVE-011 after an external committee suggested benefits may not outweigh risks; Merck confirmed the decision after reviewing all data and will also stop the broader program, including Phase 3 BELLWAVE-008 and BELLWAVE-010. Analyses are ongoing.Material DetailsCont…